Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that predictable routine of meetings, deadlines, and the like has, indeed, returned. And of course, we are coping by quaffing cups of stimulation. As always, you are invited to join us. Firing up the neurons is not a bad thing, after all. And remember, no prescription is required. Meanwhile, here are some items of interest to help you along. Hope you have a smashing day and please do stay in touch …

GlaxoSmithKline (GSK) won another reprieve for its blockbuster Advair lung drug after the Food and Drug Administration insisted Hikma Pharmaceuticals (HIK) conduct a further clinical study evaluating its generic version of the drug, Reuters writes. Hikma expects to submit a response to the agency with new clinical data in 2019, which means a potential launch could come in 2020 if all goes well. Hikma already faced a delay for its generic last year, as did generic drug company Mylan. Last month, a third Advair copy from Novartis’s Sandoz division also got knocked back by the FDA.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy